Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Cimzia

Cimzia is a medicine containing the active ingredient(s) certolizumab pegol. On this page you will find out more about Cimzia, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: certolizumab pegol

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Cimzia 200 mg/mL injection solution, 2 x 1 mL syringes

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Rheumatoid arthritis CIMZIA is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients. - combined with MTX in case of either an inadequate response or intolerance to previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) or - as monotherapy in case of a contraindication or intolerance to MTX (see DOSAGE AND ADMINISTRATION).,CIMZIA has been shown to reduce the rate of progression of joint damage as measured by X-ray, when given in combination with MTX.,CIMZIA in combination with MTX is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX or other DMARDs.,Psoriatic arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease-modifying anti-rheumatic drug therapy (DMARDs) has been inadequate. CIMZIA has been shown to improve physical function.,Ankylosing Spondylitis CIMZIA is indicated for the treatment of adult patients with active, ankylosing spondylitis who have been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug (NSAID).

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Clear to opalescent, colourless to yellow liquid, essentially free of visible particles.
Dosage Form Injection, solution
Route of administration Subcutaneous
Medicine schedule
2: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Syringe
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Do not Freeze,Protect from Light,Refrigerate
Life time 18 Months
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 3 results

Cimzia Solution for injection -

Cimzia Solution for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website


This Information Sheet is about some of the common medications (drugs) used to treat autoimmune illness.

Read more on Autoimmune Resource and Research Centre website

Xeljanz Tablets -

Xeljanz Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo